Alina Mărginean, Claudia Bănescu, Alina Scridon and Minodora Dobreanu
in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-9.
49. Kim KA, Park PW, Hong SJ, Park J-Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008;84:236-42.
50. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 Polymorphisms and Response to Clopidogrel. N Engl J Med. 2009;360:354-62.
51. Varenhorst C, James S, Erlinge D, et al. Genetic
, Barlow KB, Nobrega JN, Kapur S. Partial agonists in schizophrenia--why some work and others do not: insights from preclinical animal models. Int J Neuropsychopharmacol 14, 1165–1178, 2011.
Nemeroff CB, Kinkead B, Goldstein J. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry 63 (Suppl 13), 5–11, 2002.
Nomikos GG, Tham CS, Fibiger HC, Svensson TH. The puta in rat medial prefrontal cortex and lateral tive atypical antipsychotic drug amperozide preferentially increases c-fos expression septum
Henu Kumar Verma, Saikrishna Lakkakula and Bhaskar V.K.S. Lakkakula
pharmacokinetics of HU indicate that the renal impairment results in increased systemic exposure and decreased urinary recovery of the drug [ 16 ]. Some patients receiving HU therapy showed mild albuminuria, with an increase in white cells and granular casts, as well as occasional red cells, in the urine [ 76 ]. However, the BABY HUG trial demonstrated that HU is associated with better urine-concentrating ability and less renal enlargement, in addition to improvement in overall renal function [ 58 ]. Studies in animal models revealed that that HU therapy inhibits spermatogenesis
Alexander A. Vitin, Leonard Azamfirei, Dana Tomescu and John D. Lang
. Pharmacokinetics and pharmacodynamics of dichloroacetate in patients with cirrhosis. Clin Pharmacol Ther 1999;66:380-390.
55. Nahas GG1, Sutin KM, Fermon C, et al. Guidelines for the treatment of acidaemia with THAM. Drugs. 1998;55:191-224.
56. Hoste EA, Colpaert K, Vanholder RC, et al. Sodium bicarbonate versus THAM in ICU patients with mild metabolic acidosis. J Nephrol. 2005;18:303-307.
57. Kraut J A, Madias NE. Treatment of acute metabolic acidosis: a pathophysiologic approach Nat. Rev. Nephrol 2012
Michał Taszner, Agata Szymańska and Maria Bieniaszewska
] schedule, and pharmacokinetics would improve outcome in patients with large B-cell lymphomas. A prospective multi-institutional study of administration of etoposide, vincristine, and doxorubicin for 96 hours with bolus doses of cyclophosphamide and oral prednisone (EPOCH therapy. Schemat chemioterapii EPOCH z podaniem leków w dawkach dostosowywanych, z lub bez dodatku rituximabu (DA-EPOCH(-R), dose adjusted -EPOCH - rituximab) jest leczeniem wykorzystującym długotrwałą infuzję cytostatyków, z modyfikacją dawek w kolejnych cyklach na podstawie obserwowanych parametrow
Paweł Łaguna, Anna Klukowska, Jarosław Ćwikła and Michał Matysiak
with hemophilia A with inhibitors: results from the HAVEN 2 study Blood 2018 132 suppl 1 632 (abstr)
 Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 2019. Published online April 16, 2019.
Pipe SW Shima M Lehle M et al Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre
Aneta Neskoromna-Jędrzejczak, Katarzyna Bogusiak, Krzysztof Chojnowski, Marta Robak and Jacek Treliński
subcommittee of factor VIII and factor IX of the scientific and standarization committee of the International Society on Thrombosis and Haemostasis Thromb Haemost. 2001 85 560
 Lehmann-Kopydlowska M, Zawilska K. Dental guidelines in congenital hemophilia A and B. Czas Stomatol. 2010;63(6):345-357. Lehmann-Kopydlowska M Zawilska K. Dental guidelines in congenital hemophilia A and B Czas Stomatol. 2010 63 6 345 357
 Bjorkman S, Carlsson M, Berntop E. Pharmacokinetics of factor IX in patients with haemophilia B: Methodological aspects and physiological interpretation
Cristina Petrișor, Sebastian Trancă, Andreea Cordoș and Vasile Bințințan
neurosurgical consultation. The patient and the family disclosed that the patient had not had any prior cranial imaging since the initial traumatic event.
It is not entirely clear if the increased susceptibility to postoperative low-dose PCA morphine-induced respiratory depression in the patient with a large undiagnosed post-traumatic porencephalic cyst was due to functional changes in the pharmacokinetics and pharmacodynamics related to the structural changes of the brain.
A porencephalic cyst is a cavity in the cerebral hemisphere filled with
Ioana-Aurița Albu-Stan, Daniel-Emil Albu, Diana Cerghizan, Lia Yero Eremie, Kinga Jánosi, Monica Baloș and Constantin Copotoiu
of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res . 2007;86:1022.
34. Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone . 2011;48:677.
35. Suzuki K, Takeyama S, Sakai Y, Yamada S, Shinoda H. Current topics in pharmacological research on bone metabolism: inhibitory effects of bisphosphonates on the differentiation and activity of osteoclasts. J Pharmacol Sci . 2006;100:189.
36. Ito M, Amizuka N
Iwona Hus, Joanna Drozd-Sokołowska, Lidia Gil, Ewa Lech-Marańda, Krzysztof Giannopoulos, Sebastian Giebel, Wojciech Jurczak, Tomasz Wróbel, Jan Maciej Zaucha and Tadeusz Robak
Kanakasetty GB et al Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study Lancet Haematol 2017 4 e350 61
 Kim WS, Buske C, Ogura M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol 2017;4:e362